Holen Sie sich die Stockscreener-App
1.57
6.55%
-0.11
Schlusskurs vom Vortag:
$1.68
Offen:
$1.67
24-Stunden-Volumen:
7.22M
Relative Volume:
0.40
Marktkapitalisierung:
$233.28M
Einnahmen:
$424.90K
Nettoeinkommen (Verlust:
$-94.02M
KGV:
-0.632
EPS:
-2.4842
Netto-Cashflow:
$-51.25M
1W Leistung:
+8.28%
1M Leistung:
+76.40%
6M Leistung:
+166.10%
1J Leistung:
-22.28%
1-Tages-Spanne:
$1.55
$1.68
1-Wochen-Bereich:
$1.30
$1.8701
52-Wochen-Spanne:
$0.1611
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.57 | 233.28M | 424.90K | -94.02M | -51.25M | -2.4842 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-02 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-27 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-08-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-13 | Eingeleitet | CapitalOne | Overweight |
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Outlook Therapeutics Stock (OTLK) Opinions on Phase 3 Advancement - Quiver Quantitative
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits
OTLK Stock Holds Nasdaq Compliance As FDA Clock Starts - StocksToTrade
Outlook Therapeutics | D: Filing D - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Outlook Therapeutics files dispute resolution request with FDA - Investing.com
Enterprise value to revenue forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
Why Is OTLK Stock Falling Today? - Stocktwits
Outlook Therapeutics Stock (OTLK) Opinions on FDA Review for Lytenava - Quiver Quantitative
Outlook Therapeutics Regains Nasdaq Compliance - marketscreener.com
Outlook Therapeutics Regains Nasdaq Minimum Bid Compliance - The Globe and Mail
OTLKOutlook Therapeutics Inc Latest SEC Filings - Finviz
Outlook Therapeutics (OTLK) Regains Compliance with Nasdaq Minimum Bid Price Requirement – 8-K Filing June 2026 – Minichart - Minichart
Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Outlook Therapeutics (OTLK) restores Nasdaq minimum bid compliance, delisting threat closed - Stock Titan
OTLK Stock Climbs As FDA Fast-Tracks Lytenava Decision - StocksToTrade
Enterprise value to EBITDA forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
Outlook Therapeutics, Inc. Actuals & Estimates (NASDAQ:OTLK) - TradingView
OTLK stock up 35% as FDA accepts resubmitted eye drug BLA for review - MSN
Outlook Therapeutics, Inc. Actuals & Estimates (FWB:41O) - TradingView
Enterprise value to revenue forward of Outlook Therapeutics, Inc. – MUN:41O - TradingView
Price to sales forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
Price to earnings forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
Price to earnings forward of Outlook Therapeutics, Inc. – MUN:41O - TradingView
Price to sales forward of Outlook Therapeutics, Inc. – MUN:41O - TradingView
Enterprise value to EBIT forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
OTLK Forecast — Price Target — Prediction for 2027 - TradingView
41O Forecast — Price Target — Prediction for 2027 - TradingView
Outlook Therapeutics Inc (OTLK) Valuation: PE, PB & Fair Value Analysis - TradingKey
Outlook Therapeutics Inc (OTLK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to book forward of Outlook Therapeutics, Inc. – MUN:41O - TradingView
OTLK stock soars 28% after FDA sets July date for Lytenava decision - MSN
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
Outlook Therapeutics StockWeekly review and sector context for biotech eye drug maker - AD HOC NEWS
Outlook Therapeutics Inc (OTLK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
One Month, One Drug, One Verdict: Outlook Therapeutics' Lytenava Awaits FDA's Answer on July 29 - AD HOC NEWS
Outlook Therapeutics Heads Into Another FDA PDUFA Decision For Lytenava (NASDAQ:OTLK) - Seeking Alpha
Outlook Therapeutics Secures FDA Class-1 Review for Lytenava, Yet Cash Crunch and European Slowdown - AD HOC NEWS
Outlook Therapeutics’ Lytenava Nears FDA Verdict as Shares Skyrocket — But RSI Flashes Caution - AD HOC NEWS
Outlook Therapeutics Inc (OTLK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Outlook Therapeutics Inc (OTLK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA) - Ophthalmology Times
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):